Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes [Yahoo! Finance]
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? [Yahoo! Finance]
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight [Yahoo! Finance]